Gilead Sciences Inc (GILD)
$135.47-0.55%
Spriggl Score: Good— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Patent-protected HIV franchise throwing off cash; December drug approval is the key catalyst.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor …
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $164.0B
Recent dividends
- 15 Jun 2026$0.82
- 13 Mar 2026$0.82
- 15 Dec 2025$0.79
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Gilead Sciences Inc and 1,600+ UK and US stocks.
Start free